Five things for pharma marketers to know: Thursday, February 23, 2017



1. Harvard Pilgrim Health Care signed new pay-for-performance deals with Amgen and Eli Lilly for their drugs Enbrel and Forteo, respectively, based on how effectively they treat patients. EvaluatePharma estimates that Amgen's Enbrel, used to treat rheumatoid arthritis, costs nearly $45,000 for a year of treatment and Lilly's Forteo, an osteoporosis medicine, runs about $29,000 per year. (Boston Globe)

2. A new patient advocacy group, Patients for Affordable Drugs, has launched. Its focus is lowering drug prices. Historically, patient advocacy groups have advocated for the approval of new drugs — often with industry support. (USA Today)

3. Novartis' lung-cancer drug, Zykadia, received priority review from the FDA as a first-line treatment. The drug is designed to treat patients with advanced forms of the disease and whose tumors are ALK (anaplastic lymphoma kinase) positive. (Reuters)

4. Allergan CEO Brent Saunders proposed that President Trump lead negotiations with drugmakers to lower prices. He said that the administration could waive federal antitrust rules that prohibit drugmakers from discussing pricing, and, as a result, drugmakers could create new voluntary guidelines on how to price their medicines. (Bloomberg)

5. ICYMI: A new online database, Iodine, aims to help patients find the right medicine for their condition or disease through pooled patient reviews. The database weighs a medication based on more “human” factors like side effects, convenience, availability, and whether taking the medication was “worth it.” (Forbes)